LSL Pharma enters LOI to acquire Quebec competitor

Executive Summary

• LSL Pharma Group Inc. has entered into a non-binding letter of intent (LOI) to acquire Target Co., a Quebec-based competitor specializing in the formulation and production of liquid and semi-solid natural and cosmetic products.
• The acquisition is expected to add $8 million to $10 million in annual revenues, representing a revenue increase of more than 20% for LSL Pharma, while expanding capacity and service offerings.
• Total consideration is estimated between $3 million and $3.3 million, funded by recent bank financing and the assumption of Target Co.'s bank debt, with closing expected in Q3 2025.

Key Details

• Transaction Structure: Non-binding Letter of Intent (LOI) to acquire a privately held, arm's length competitor.
• Target Company: Target Co., a Quebec-based contract manufacturer specializing in liquid and semi-solid natural and cosmetic products for Canadian and international markets.
• Consideration: Total value between $3 million and $3.3 million.
• Funding: Cash portion financed by proceeds from recently announced bank financing; transaction also involves assumption of Target Co.'s bank debt.
• Financial Impact:
  • Expected to add $8 million to $10 million in annual revenues.
  • Projected to increase consolidated revenues by more than 20% on an annual basis.
  • LSL Pharma anticipates realizing a material gain on acquisition.
• Strategic Rationale: Highly complementary to existing CDMO operations; strengthens client relationships; expands capacity and service offering; leverages head office infrastructure; expected to generate significant synergies.
• Timeline: Closing expected in Q3 2025.

Notable Quotes

• "Following the highly successful acquisition of Virage Sante and Dermolab Pharma last year, we look forward to executing this additional transaction to further expand our CDMO operations, manufacturing capabilities and customer base as more and more Canadian companies are looking for local solutions to their supply chain requirements," said Francois Roberge, president and chief executive officer of LSL Pharma.
• "Target Co. has an excellent reputation as a contract manufacturer. We expect this transaction to be accretive once fully integrated, to generate significant synergies with our existing operations as well as leverage our head office infrastructure," added Mr. Roberge.